Observational studyJournal of the American College of Cardiology2015
Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy).
Observational study in Journal of the American College of Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 208 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy
Observational Study for Outcomes for Participants With Cardiogenic Shock and Peripartum Cardiomyopathy
Who cites it
208 citing papers in PubMed, 7 syntheses or guidelines pooled it, 504 citations in OpenAlex.
- Prevalence and associated outcomes of right ventricular dysfunction in peripartum cardiomyopathy: a systematic review, meta-analysis and meta-regression.Open heart · 2025Pooled it
- Meta-analysis of cardiac magnetic resonance in prognosticating left ventricular function in peripartum cardiomyopathy.ESC heart failure · 2025Pooled it
- Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis.Current problems in cardiology · 2023Pooled it
- Prognostic value of various markers in recovery from peripartum cardiomyopathy: a systematic review and meta-analysis.ESC heart failure · 2022Pooled it
- Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis.Heart failure reviews · 2022Pooled it
- Heart failure in pregnancy: what is the long-term impact of pregnancy on cardiac function? A tertiary care centre experience and systematic review.Open heart · 2021Pooled it
- Peripartum cardiomyopathy: A systematic review of the literature.Clinical cardiology · 2018Pooled it
- Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial.BMC cardiovascular disorders · 2020Trial
- Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction.Clinical research in cardiology : official journal of the German Cardiac Society · 2019Trial
- Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study.European heart journal · 2017Trial
- Mortality and clinical outcomes in peripartum cardiomyopathy: A systematic review and meta-analysis.American heart journal plus : cardiology research and practice · 2026Review
- Women's heart and echocardiography.Journal of cardiovascular imaging · 2026Review
- Targeted Serum Organic-Acid Profiling Identifies Candidate Metabolic Signatures in Peripartum Cardiomyopathy: A Case-Control Study.International journal of molecular sciences · 2026Article
- Trends in Initial Cardiac Function, Treatment, and Outcomes in Peripartum Cardiomyopathy.The journal of obstetrics and gynaecology research · 2026Article
- Patient-Specific In Silico Prediction of Outcomes of Partial Continuous-Flow LVAD Treatment in Peripartum Cardiomyopathy.International journal for numerical methods in biomedical engineering · 2026Article
- Cardiovascular-Related Maternal Mortality.Obstetrics and gynecology · 2026Review
- Article
- Maternal Obesity and Risk of Hospital Readmission in Peripartum Cardiomyopathy: A Retrospective Cohort Study.Cureus · 2026Article
- Article
- Peripartum Cardiomyopathy: Current Insights into Pathogenesis and Clinical Management: A Narrative Review.Journal of clinical medicine · 2026Review
148 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
21 authors at 13 institutions in 1 country.
Funding
Abstract
backgroundPeripartum cardiomyopathy (PPCM) remains a major cause of maternal morbidity and mortality.
objectivesThis study sought to prospectively evaluate recovery of the left ventricular ejection fraction (LVEF) and clinical outcomes in the multicenter IPAC (Investigations of Pregnancy Associated Cardiomyopathy) study.
methodsWe enrolled and followed 100 women with PPCM through 1 year post-partum. The LVEF was assessed by echocardiography at baseline and at 2, 6, and 12 months post-partum. Survival free from major cardiovascular events (death, transplantation, or left ventricular [LV] assist device) was determined. Predictors of outcome, particularly race, parameters of LV dysfunction (LVEF), and remodeling (left ventricular end-diastolic diameter [LVEDD]) at presentation, were assessed by univariate and multivariate analyses.
resultsThe cohort was 30% black, 65% white, 5% other; the mean patient age was 30 ± 6 years; and 88% were receiving beta-blockers and 81% angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The LVEF at study entry was 0.35 ± 0.10, 0.51 ± 0.11 at 6 months, and 0.53 ± 0.10 at 12 months. By 1 year, 13% had experienced major events or had persistent severe cardiomyopathy with an LVEF <0.35, and 72% achieved an LVEF ≥0.50. An initial LVEF <0.30 (p = 0.001), an LVEDD ≥6.0 cm (p < 0.001), black race (p = 0.001), and presentation after 6 weeks post-partum (p = 0.02) were associated with a lower LVEF at 12 months. No subjects with both a baseline LVEF <0.30 and an LVEDD ≥6.0 cm recovered by 1 year post-partum, whereas 91% with both a baseline LVEF ≥0.30 and an LVEDD <6.0 cm recovered (p < 0.00001).
conclusionsIn a prospective cohort with PPCM, most women recovered; however, 13% had major events or persistent severe cardiomyopathy. Black women had more LV dysfunction at presentation and at 6 and 12 months post-partum. Severe LV dysfunction and greater remodeling at study entry were associated with less recovery. (Investigations of Pregnancy Associated Cardiomyopathy [IPAC]; NCT01085955).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.